MMJ's CEO, Duane Boise commented on the company's milestone achievement, "the filing of these applications with the FDA brings us one step closer to helping persons suffering from these debilitating diseases.
RESTON, Va. (PRWEB) August 24, 2018
MMJ International Holdings, the premier medical sciences research company that is currently advancing the science of medical marijuana through patient clinical research, announced today that it has filed filed (2) Applications with the FDA to begin clinical trials aimed at treating symptoms associated with Multiple Sclerosis and Huntington’s Disease.
MMJ is seeking FDA permission to proceed to undertake a clinical research study to develop a pharmaceutical grade cannabis based medicine derived from the natural extracts of the marijuana plant.
MMJ’s lead medical investigators will conduct one of the first ever clinical trials to investigate and prove efficacy of a natural botanical cannabis extract as a treatment for Multiple Sclerosis and Huntington’s Disease. MMJ will be providing new evidence regarding clinical outcomes leading to a commercial drug development success. MMJ anticipates that the clinical trials will show positive effects.
Multiple Sclerosis and Huntington’s Disease are debilitating neuro-degenerative disorders. Although the diseases progress slowly, patients have difficulty moving, suffer from involuntary tremors, and reduced cognitive functioning. Initial investigative research has shown that cannabidiol (CBD), a non-psychoactive component of the cannabis oil, displays neuro protective qualities. MS and Huntington’s Disease have no known cure and limited drugs are available for treatment.
MMJ's CEO, Duane Boise commented on the company's milestone achievement, "the filing of these applications with the FDA brings us one step closer to helping persons suffering from these debilitating diseases. As a company, we are committed to researching and developing cannabis based medicines which will improve the lives of people around the world."
Boise further stated that, "The MMJ team expects many advantages by requesting a pre-IND meeting." Per the FDA, a pre-IND meeting can reduce the time to market for our product by: Identifying and avoiding unnecessary studies, providing the opportunity for creative exchange of ideas, and gaining the support from the FDA for our proposed study strategy.
Mr. Boise also took the opportunity to commend MMJ's team network of world leading scientists and industry experts that have positioned MMJ to be a leader in the research and development of plant derived cannabinoid formulations". He added, "our unique scientific approach sets us apart from others in the industry and we are working hard to create new and innovative pathways geared towards helping doctors treat and alleviating the suffering of patients."
Media contact:
Ann Marie Ganness
media(at)mmjih.com
800-586-7863
SOURCE:MMJ International Holdings